AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00648388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pletal® Tablets 100 mg
Description: 100 single dose fasting
Study NCT04538118 — intervention group
Intervention type: BEHAVIORAL
Intervention: Shoulder disability
Description: Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks.
Study NCT04538118 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Range of Motion
Description: Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks.
Study NCT04538118 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain Intensity
Description: Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks.
Study NCT03800537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Fingerprinting
Description: The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
Study NCT03116035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based decision aid
Description: Patients were randomized to receive links to a commercially available decision aid.
Study NCT03116035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard websites
Description: Patients were randomized to receive links to standard, high-quality websites.
Study NCT01006655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate HFA
Description: 100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
Study NCT01006655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inhalation twice a day for one month, preceded and followed by adenosine challenge test
Study NCT00613327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride OROS
Description: Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
Study NCT03160248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
Study NCT03160248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
Study NCT03727022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Study NCT03727022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
Study NCT03851887 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAI combine SBRT
Description: TAI combine SBRT
Study NCT03203824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dark chocolate
Description: Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
Study NCT03203824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non dark chocolate
Description: No dark chocolate will be given to this group during the procedures.
Study NCT03828097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental supplement
Description: Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
Study NCT03828097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
Study NCT01674049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immediate Nutrition
Description: Nutritional supplement consumed either immediately following a 40min resistance exercise bout
Study NCT01674049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition 3 hours Post-Bout
Description: Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
Study NCT01674049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: A single 40 minute circuit-style bout of resistance exercise
Study NCT01674049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: A single 40 minute circuit-style bout of resistance exercise
Study NCT03652363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glial cell line-derived neurotrophic factor
Description: Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
Study NCT03652363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glial cell line-derived neurotrophic factor
Description: Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
Study NCT00395486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10mg
Study NCT00395486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 10mg
Study NCT00683930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil 2 g/Day
Description: Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
Study NCT00683930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) 3 g/Day
Description: Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
Study NCT00683930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
Study NCT03628105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CR Before Exposure
Description: Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study.
Study NCT03628105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CR After Exposure
Description: Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
Study NCT01145001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Weekly CBT for all subjects
Study NCT01145001 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: Weekly CBT for all subjects
Study NCT02411006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment mailing
Description: Ask people to commit to their upcoming medication adherence
Study NCT02593149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearGuard HD End Cap
Description: The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
Study NCT02146469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses with an 3 months interval
Description: varicella vaccination
Study NCT02146469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A second dose with an 1 year interval
Description: varicella vaccine
Study NCT02146469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A second dose with an 3 year interval
Description: varicella vaccine
Study NCT02146469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A second dose with an 5 year interval
Description: varicella vaccine
Study NCT02146469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose Varicella vaccine and 1 dose MMR given at the same time
Description: varicella vaccine and MMR
Study NCT02146469 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 1 dose MMR
Description: MMR
Study NCT02282709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: 60 mg once daily
Study NCT02282709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asunaprevir
Description: 100 mg BID
Study NCT02808403 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention; observation of routine medical care
Study NCT01420497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular infiltration
Description: intra articular infiltration
Study NCT01420497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural infiltration
Description: epidural infiltration
Study NCT02180815 — intervention group
Intervention type: DEVICE
Intervention: ReVENT Sleep Apnea System
Study NCT03169933 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Combined, intensified and modulated adjuvant radiotherapy
Study NCT02411006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Remind people to take their medicine
Study NCT03730818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based Exercise Group
Description: The intervention will consist of a land-based exercise protocol
Study NCT03878979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 480mg and surgical resection
Description: One dose of Nivolumab 480mg given four weeks prior to surgical resection.
Study NCT01229384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure nebulization
Description: Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
Study NCT01229384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard passive nebulization of respiratory medications
Description: Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
Study NCT06274086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-session catheter-directed sclerotherapy
Description: After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~* An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~* A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~* A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook).
Study NCT00110552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvia officinalis (sage)
Description: oral dosage
Study NCT01693211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)
Description: Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
Study NCT01693211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual (CCC technique with Utrata forceps)
Description: Capsulorhexis and pre-fragmentation are performed manually.
Study NCT00249769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)
Description: Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
Study NCT01145001 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: incentives given for abstinence based on urine analysis
Study NCT01145001 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: incentives given for abstinence based on urine analysis
Study NCT01145001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Transdermal Patch
Description: 14mg ir 21mg doses based on weight and #cigs/day
Study NCT00713778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian cystectomy
Description: Laparoscopic ovarian cystectomy using bipolar
Study NCT00713778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian cystectomy
Description: Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
Study NCT02411006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anonymity
Description: Keep patient predictions and commitment anonymous
Study NCT02411006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identification
Description: Ask patients to report their predictions and commitments
Study NCT02061163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Ultrasound
Description: Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
Study NCT02061163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison
Description: Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
Study NCT00713778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian cystectomy
Description: Laparotomic ovarian cystectomy using suture
Study NCT00114764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Filgrastim given daily after induction chemotherapy
Study NCT00114764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Pegfilgrastim given once after induction chemotherapy
Study NCT02259764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL - single rising dose
Study NCT02259764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02259764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized high fat meal
Study NCT00408772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT02619955 — intervention group
Intervention type: OTHER
Intervention: samples with DNA
Study NCT00249769 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles Vaccine (MV)
Description: The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979.
Study NCT01198431 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep duration
Description: Duration of sleep per night
Study NCT00408772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00408772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT01198431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration
Description: Duration of sleep per night
Study NCT00408772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00408772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00408772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study NCT00405275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: etanercept, subcutaneous injection
Study NCT02157116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT04667598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified Wenxin Decoction
Description: Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
Study NCT04667598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Wenxin Decoction
Description: Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
Study NCT00005947 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
Study NCT00005947 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
Study NCT01545791 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
Study NCT00741897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine: One 30 mg Tablet once daily for two weeks
Study NCT00810277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 24 weeks
Study NCT00869791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX066
Description: experimental drug product: extended-release carbidopa-levodopa capsules
Study NCT00869791 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IR CD-LD
Description: active comparator: immediate-release carbidopa-levodopa capsules
Study NCT02485249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic
Description: Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)